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Abstract 
Gold(III) complexes with 1,7- and 4,7-phenanthroline ligands, [AuCl3(1,7-phen-κN7)] (1) 
and [AuCl3(4,7-phen-κN4)] (2) were synthesized and structurally characterized by 
spectroscopic (NMR, IR and UV-vis) and single-crystal X-ray diffraction techniques. In 
these complexes, 1,7- and 4,7-phenanthrolines are monodentatedly coordinated to the 
Au(III) ion through the N7 and N4 nitrogen atoms, respectively. In comparison to the 
clinically relevant anti-angiogenic compounds auranofin and sunitinib, gold(III)-
phenanthroline complexes showed from 1.5- to 20-fold higher anti-angiogenic potential, 
and 13- and 118-fold lower toxicity. Among the tested compounds, complex 1 was the 
most potent and may be an excellent anti-angiogenic drug candidate, since it showed 
strong anti-angiogenic activity in zebrafish embryos achieving IC50 value (concentration 
resulting in an anti-angiogenic phenotype at 50% of embryos) of 2.89 µM, while had low 
toxicity with LC50 value (the concentration inducing the lethal effect of 50% embryos) of 
128 µM. Molecular docking study revealed that both complexes and ligands could 
suppress angiogenesis targeting the multiple major regulators of angiogenesis, such as the 
vascular endothelial growth factor receptor (VEGFR-2), the matrix metalloproteases 
(MMP-2 and MMP-9), and thioredoxin reductase (TrxR1), where the complexes showed 
higher binding affinity in comparison to ligands, and particularly to auranofin, but 
comparable to sunitinib, an anti-angiogenic drug of clinical relevance. 
 
Keywords: Gold(III) complexes, Phenanthroline, Cytotoxicity, Embryotoxicity, 
Angiogenesis 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 3 
1. Introduction 
Angiogenesis is a physiological process of the sprouting of new blood capillaries from 
preexisting vessels, which involves endothelial cells activation, invasion, migration, 
proliferation, tube formation and, finally, capillary network establishment [1]. While 
controllable and balanced angiogenesis play an essential role in normal physiological 
processes, an excessive activation of angiogenesis leads to numerous pathological 
processes, such as inflammatory disease, rheumatoid arthritis, psoriasis, artherosclerosis, 
diabetic retinopathy and cancer, for which growth, invasion and metastasis is crucial to 
form new vessels [2]. Accordingly, the blockade of angiogenesis by targeting activated 
endothelial cells and inhibiting them to proliferate and migrate is a proven strategy for the 
treatment of angiogenesis-related diseases [3]. It is evidenced that angiogenesis inhibitors 
combined with adjuvant chemotherapy increased its efficacy and provided significantly 
better survival of the cancer patients [4]. So far, more than 300 angiogenesis inhibitors 
have been developed, and 80 anti-angiogenic drugs are currently in clinical trials [5]. 
However, the drawbacks of many anti-angiogenic therapies, mostly associated with clinical 
resistance and toxicity, particularly cardiotoxicity [6], highlight the need for developing 
new drug candidates with improved bioactivity and a more favorable safety profile. 
In recent years, the metal-based chemotherapeutics has undergone a renaissance, yet 
offering excellent and unexplored opportunities for further drug discovery [7]. In this vein, 
gold-based compounds present a very promising family of cytotoxic and potentially 
anticancer agents [8-10]. While many gold(III)-complexes containing organic heterocyclic 
ligands were proven for substantial anticancer activity [8,9], an anti-angiogenic activity has 
been demonstrated only for few of them including complexes with porphyrins, 
phenylpyridines, Schiff-base ligands [11-15] and, recently, with L-histidine-containing 
dipeptides [16]. One of the successful approaches in the anti-angiogenic gold(III) 
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complexes design might be relied on the use of ligands with proven anti-angiogenic 
activity, while keeping desired toxicological profiles. 
An important class of ligands for the synthesis of gold(III) complexes comprises 
aromatic nitrogen-containing heterocycles (N-heterocycles), since they represent structural 
moieties of many natural products and biologically active compounds possessing diverse 
pharmacological properties, such as antitumor, antimicrobial, anticonvulsant, anti-
inflammatory and anti-angiogenic [17-20]. Among these compounds, 1,10-phenanthroline 
(1,10-phen) has been the most extensively explored and frequently used owing to its planar 
structure, metal chelating properties, capability to bind to DNA by intercalation and 
cytotoxic activity against numerous cancer cell lines [21-29]. However, the previous 
studies revealed that 1,10-phen and the corresponding gold(III) complex, [Au(1,10-
phen)Cl2]Cl, had no selective activity against tumor cell lines in comparison to normal 
human and mammalian cell lines [22,24,26,27], whereas 1,10-phen exerted equal to or 
even higher cytotoxicity on cancer cell lines than the corresponding platinum(II) and 
gold(III) complexes [25,26]. Recently, Ellis and Crawford [20] found that 1,10-phen 
possesses ability to inhibit blood vessels development in zebrafish embryos, eliciting the 
toxic response in embryos upon an effective anti-angiogenic concentrations. All these 
biological properties limit the future application of 1,10-phen as a ligand for design and 
synthesis of metal-based anti-angiogenic drugs. 
Owing to high molecular, genetic and physiological similarity between zebrafish and 
mammals, including humans, zebrafish emerged as reliable and very predictive high-
throughput model system in early drug discovery process [30], enabling identification of 
molecules with potential therapeutic effect on the certain targets and elimination of those 
with toxic effect [31,32]. As the vascular system is highly conserved between zebrafish 
and mammals and requires the same necessary proteins for blood vessel growth, zebrafish 
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emerged also as a powerful platform for the identification of novel angiogenesis inhibitors 
[33,34]. 
Based on the discovery of anti-angiogenic property of 1,10-phen [20], and prompted by 
findings that phenanthrolines with differentially positioned nitrogen atoms, such as 1,7-
phenanthroline (1,7-phen) and 4,7-phenanthroline (4,7-phen), are significantly less toxic, 
mutagenic and genotoxic than 1,10-phen [35,36], but nevertheless have not been used for 
the synthesis of gold(III) complexes, we decided to synthesize two new gold(III) 
complexes, [AuCl3(1,7-phen-κN7)] (1) and [AuCl3(4,7-phen-κN4)] (2). These complexes 
were characterized by NMR (
1
H and 
13
C), IR and UV-vis spectroscopic and single-crystal 
X-ray diffraction analysis. DFT calculations were employed in order to explain 
coordination mode of 1,7- and 4,7-phen toward the AuCl3 fragment. Both phenanthroline 
ligands and gold(III) complexes were explored for their cytotoxic properties and the 
capabilities to inhibit the migration of endothelial cells in vitro and the angiogenesis in vivo 
in zebrafish (Danio rerio) embryos, which were also used for the toxicity assessment. 
Their anti-angiogenic activities have been compared to those of auranofin and sunitinib, 
the two drugs of clinical relevance and with anti-angiogenic properties. In addition, in 
silico study was performed to evaluate the potential of the gold(III) complexes and the 
corresponding phenanthroline ligands to bind some of the most important targets 
implicated in the process of angiogenesis such as vascular endothelial growth factor 
receptors (VEGFRs), the matrix metalloproteases (MMPs) and thioredoxin reductases 
(TrxRs). 
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2. Experimental 
2.1. Materials 
Distilled water was demineralized and purified to a resistance of greater than 10 
M.cm. Potassium tetrachloridoaurate(III) (K[AuCl4]), 1,7-phenanthroline (1,7-phen), 4,7-
phenanthroline (4,7-phen), ethanol, acetonitrile, dimethylformamide (DMF) and acetone-d6 
were purchased from the Sigma-Aldrich. All the employed chemicals were of analytical 
reagent grade and used without further purification. 
 
2.2. Measurements 
Elemental microanalyses of the synthesized gold(III) complexes for carbon, hydrogen 
and nitrogen were performed by the Microanalytical Laboratory, Faculty of Chemistry, 
University of Belgrade. All NMR spectra were recorded at 25 C on a Bruker Avance III 
400 MHz spectrometer. 5 mg of each compound was dissolved in 0.6 mL of acetone-d6 and 
transferred into a 5 mm NMR tube. Chemical shifts are reported in ppm () and scalar 
couplings are reported in Hertz. The IR spectra were recorded as KBr pellets on a Perkin 
Elmer Spectrum One spectrometer over the range 450 – 4000 cm-1. The far-IR spectra 
were measured on a Perkin Elmer 983 spectrophotometer using Nujol mull supported 
between CsI sheets. The UV-vis spectra were recorded on a Perkin Elmer Lambda 35 
double-beam spectrophotometer equipped with thermostated 1.00-cm quartz Suprasil cells 
after dissolving the gold(III) complexes 1 and 2 in DMF, over the wavelength range of 200 
– 600 nm. The concentration of the gold(III) complexes was 2.5.10-4 M.  
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2.3. Synthesis of gold(III) complexes 1 and 2 
Gold(III) complexes, [AuCl3(1,7-phen-κN7)] (1) and [AuCl3(4,7-phen-κN4)] (2), were 
synthesized according to the modified procedure for the preparation of [AuCl3(N-
heterocycle)] complexes [37]. 
The solution of 0.25 mmol of the corresponding N-heterocyclic ligand (45.0 mg, 1,7-
phen for 1 and 4,7-phen for 2) in 5.0 mL of ethanol was added slowly under stirring to the 
solution containing an equimolar amount of K[AuCl4] (94.5 mg in 5.0 mL of ethanol). The 
resulting yellow solution was stirred in the dark at ambient temperature for 5 h. The 
formed yellow precipitate was filtered off, washed with water and dissolved in acetonitrile. 
The obtained solution was left in a refrigerator and, after a few days, yellow crystals 
suitable for single-crystal X-ray crystallography were formed. These were filtered off and 
dried in the dark at ambient temperature. The yield was 63% for 1 (76.2 mg) and 54% for 2 
(65.3 mg). 
Anal. calcd. for 1 = C12H8AuCl3N2 (Mr = 483.52): C, 29.81; H, 1.67; N, 5.79. Found: C, 
29.62; H, 1.85; N, 6.01%. 
1
H NMR (400 MHz, CD3COCD3): δ = 7.98 (dd, J = 8.2, 4.4 Hz, 
H-4), 8.36 (dd, J = 8.2, 5.7 Hz, H-10), 8.70 (d, J = 9.4 Hz, H-3), 8.75 (dd, J = 8.2, 1.7 Hz, 
H-5), 8.89 (d, J = 9.3 Hz, H-9), 9.28 (dd, J = 4.4, 1.7 Hz, H-2), 9.83 (dd, J = 5.7, 1.4 Hz, 
H-8), 10.20 ppm (d, J = 8.2 Hz, H-6). 
13
C NMR (101 MHz, CD3COCD3): δ = 123.78 (C-
9), 124.85 (C-4), 125.12 (C-10), 126.66 (C-4a), 131.05 (C-10a), 134.69 (C-3), 137.08 (C-
5), 139.37 (C-6), 143.96 (C-1a), 150.99 (C-6a), 151.97 (C-2), 152.80 ppm (C-8). IR (KBr, 
ν, cm-1): 3078(m), 2921(m), 2852(w), 1614(s), 1601(s), 1515(m), 1497(s), 1435(s), 
1417(w), 1399(m), 1296(s), 1259(w), 1231(w), 1107(m), 1051(w), 1001(w), 883(w), 
858(w), 836(s), 830(s), 796(s), 786(vs), 723(w), 514(w). Far-IR (CsI, ν, cm-1): 363(s), 340 
(sh). UV-vis (DMF, λmax, nm): 322.0 (ε = 4.0
.
10
3
 M
-1
cm
-1
). 
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Anal. calcd. for 2 = C12H8AuCl3N2 (Mr = 483.52): C, 29.81; H, 1.67; N, 5.79. Found: C, 
29.51; H, 1.66; N, 6.05%. 
1
H NMR (400 MHz, CD3COCD3): δ = 8.00 (dd, J = 8.5, 4.4 Hz, 
H-10), 8.37 (dd, J = 8.4, 5.7 Hz, H-1), 8.73 (d, J = 9.5 Hz, H-6), 9.08 (d, J = 9.6 Hz, H-5), 
9.25 (dd, J = 4.4, 1.5 Hz, H-9), 9.47 (d, J = 8.3 Hz, H-8), 9.82 (dd, J = 5.7, 1.2 Hz, H-2), 
9.94 ppm (d, J = 8.4 Hz, H-3). 
13
C NMR (101 MHz, CD3COCD3): δ = 123.96 (C-10), 
124.98 (C-1), 125.47 (C-10a), 126.88 (C-5), 131.05 (C-1a), 132.16 (C-8), 137.00 (C-6), 
138.57 (C-3), 147.49 (C-6a), 149.52 (C-4a), 152.05 (C-2), 152.96 ppm (C-9). IR (KBr, ν, 
cm
-1
): 3077(w), 3058(w), 3039(w), 3005(w), 2965(w), 1582(m), 1527(w), 1498(vs), 
1450(m), 1410(m), 1389(w), 1341(w), 1300(s), 1263(w), 1112(w), 1060(w), 825(s), 
803(s), 751(w), 565(w), 541(w). Far-IR (CsI, ν, cm-1): 359(s), 342 (sh). UV-vis (DMF, 
λmax, nm): 321.0 (ε = 3.6
.
10
3
 M
-1
cm
-1
). 
  
2.4. Crystallographic data collection and refinement of the structures  
Crystal data for 1 and 2 are provided in Table S1. Intensity measurements have been 
carried out on XCALIBUR diffractometer equipped with Mo X-ray tube and graphite 
monochromator [38]. Crystals of 2 appeared to be twinned and this has been accounted for 
by the “Twinning – multi-crystals” procedure implemented into the CrysAlis program [38]. 
In addition to the routinely applied absorption corrections, semiempirical absorption 
corrections were performed for 1. An analogous absorption correction for the X-ray data 
for 2 appeared difficult to apply, for this data set has already been subjected to the 
untwining procedure. Following structure solution with SHELXT [39], positional 
parameters and anisotropic temperature factors were refined against F
2
 with SHELXL [40]. 
Hydrogen atoms were included at calculated sites with U values equal to 1.2 times the 
value of the equivalent isotropic temperature factor of the parent C atom. 
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2.5. Quantum-mechanical methods 
The M06-2X functional in combination with the conductor-like solvation model 
CPCM [41] was used to optimize the geometries and to perform the frequency 
calculations of the examined systems in the ethanol solution (dielectric constant of 
ethanol at 298.15 K is 24.852). In all calculations the LanL2TZ(f) basis set for the 
gold and cc-pVTZ basis set for all other atoms were employed. These calculations 
were performed using the Gaussian 09 program package [42]. 
The dual descriptor can give information about the ability of a molecule to donate/accept 
electrons in a given chemical reaction [43,44]. Positive values of the dual descriptor 
correspond to electrophilic regions, while negative ones correspond to nucleophilic regions 
in a molecule. In the case of planar molecules, σ- and π-electrons give clearly 
distinguishable contributions to the calculated electronic densities. In the present work, the 
σ- and π-contributions of the dual descriptor were employed. Calculations of dual 
descriptors were performed using our own Fortran routines requiring as input formatted 
checkpoint files from Gaussian 09. 
 
2.6. Evaluation of cytotoxicity by MTT assay 
Cytotoxicity in terms of the antiproliferative effect was tested by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [45]. The assay was 
carried out using human lung fibroblasts (MRC5), human cervix cancer (HeLa), lung 
cancer (A549) and human immortalized endothelial-like EA.hy926 cell lines after 48 h of 
cell incubation in the medium, containing compounds at concentrations ranging from 0.25 
to 200 μM. Briefly, MRC5, HeLa and A549 cells were maintained in RPMI-1640 medium 
supplemented with 100 μg/mL streptomycin, 100 U/mL penicillin and 10% (v/v) fetal 
bovine serum (FBS) (all from Sigma, Munich, Germany) as a monolayer (1 × 10
4
 cells per 
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well). EA.hy926 cell line was maintained in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and HAT supplement (Gibco-
BRL) as a monolayer (1 × 10
4
 cells per well). All cell lines were grown in humidified 
atmosphere of 95% air and 5% CO2 at 37 °C. The MTT assay was performed two times in 
four replicates. The extent of MTT reduction was measured spectrophotometrically at 540 
nm using a Tecan Infinite 200 Pro multiplate reader (Tecan Group Ltd., Männedorf, 
Switzerland), and the cell survival was expressed as percentage of the control (untreated 
cells). Cytotoxicity was expressed as the concentration of the compound inhibiting cell 
growth by 50% (IC50) in comparison to untreated control. 
 
2.7. Wound-scratch migration assay 
EA.hy926 cells (3 × 10
5
)
 
were cultured as confluent monolayers in DMEM 
supplemented with 10% FBS, synchronized in 1% FBS for 24 h and wounded by removing 
a 300- to 500 μm-wide strip of cells across the well with a standard 200 μL pipette tip [46]. 
Wounded monolayers were washed twice with phosphate-buffered saline (PBS) to remove 
non-adherent cells and then treated with 200 M gold(III) complexes 1 and 2, the 
respective phenanthroline ligands and K[AuCl4], as well as with 5 µM auranofin for 6 h. 
EA.hy926 cell migration into the wounded area was photographed at the indicated times at 
the same spot with an DM IL LED Inverted Microscope equipped with a digital camera 
(Leica Microsystems, Wetzlar, Germany). The extent of healing was defined as the ratio of 
the difference between the original and the remaining wound areas compared with the 
original wound area. The closure of the gap distance was quantified using Leica 
Application Suite V4.3.0 (Leica Microsystems). 
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2.8. Embryotoxicity and anti-angiogenic potential evaluation in zebrafish model 
Assessment of toxicity and anti-angiogenic activity of gold(III) complexes on zebrafish 
embryos model was carried out according to general rules of the OECD Guidelines for the 
Testing of Chemicals [47]. All experiments involving zebrafish were performed in 
compliance with the European directive 86/609/EEC and the ethical guidelines of the 
Guide for Care and Use of Laboratory Animals of the Institute of Molecular Genetics and 
Genetic Engineering, University of Belgrade. 
Adult zebrafish (Danio rerio, wild type) were obtained from a commercial supplier (Pet 
Center, Belgrade, Serbia), housed in a temperature- and light-controlled facility with 28 °C 
and standard 14:10-hour light-dark photoperiod, and regularly fed with commercially dry 
flake food (TetraMin
TM
 flakes; Tetra Melle, Germany) twice a day and Artemia nauplii 
once daily. Zebrafish embryos were produced by pair-wise mating, collected and 
distributed into 24-well plates containing 10 embryos per well and 1 mL embryos water 
(0.2 g/L of Instant Ocean
®
 Salt in distilled water), and raised at 28 °C. For assessing lethal 
and developmental toxicity, embryos at 6 hours post fertilization (hpf) stage were treated 
with eight concentrations of gold(III) complexes 1 and 2, K[AuCl4], 1,7- and 4,7-phen 
(2.5, 5, 10, 20, 40, 60, 80 and 100 μM), and five concentrations of auranofin (1.25, 2.5, 5, 
7.5 and 10 µM). DMF (0.035%) and DMSO (0.1%) were used as negative controls. 
Experiments were performed three times using 20 embryos per concentration.  
Apical endpoints for the toxicity evaluation (Table S2) were recorded at 24, 48, 72, 96 
and 114 hpf using an inverted microscope (CKX41; Olympus, Tokyo, Japan). Dead 
embryos were counted and discarded every 24 h. At 114 hpf, embryos were inspected for 
heartbeat rate, anesthetized by addition of 0.1% (w/v) tricaine solution (Sigma-Aldrich, St. 
Louis, MO), photographed and killed by freezing at -20 °C for ≥ 24 h.  
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Anti-angiogenic potential of tested compounds was assessed using transgenic zebrafish 
embryos Tg(fli1:EGFP) expressing enhanced green fluorescent protein (EGFP) in 
endothelial cells. Embryos of Tg(fli1:EGFP) zebrafish were kindly provided by Dr. Ana 
Cvejic (Wellcome Trust Sanger Institute, Cambridge, UK) and raised in our zebrafish 
facility to adult stage under previously described life conditions. Transgenic embryos used 
in this assay were generated by natural spawning of wild type and Tg(fli1:EGFP) adults 
and reared in embryo water at 28 °C. Embryos staged at 20 hpf were dechorionated with 
fine tweezers immediately prior to drug treatment, arrayed in 24-well plate with 10 
embryos per well, and incubated with 1 mL of embryo water per well containing various 
concentration of drugs (2.5, 5, 10, 17.5 µM) at 28 °C. 0.035% DMF was used as negative 
control. After drug treatments, zebrafish embryos were anesthetized with 0.003% tricaine 
(Sigma-Aldrich) and subsequently photographed. The intersegmental blood vessels (ISVs) 
and subintestinal vessel plexus (SIVs) development were inspected and imaged in embryos 
at 48 and 72 hpf, respectively under a fluorescence microscope (Olympus BX51, Applied 
Imaging Corp., San Jose, CA, USA). Auranofin (Sigma-Aldrich) and sunitinib (Sutent, 
Pfizer, New York) were used as positive controls with known anti-angiogenic activity 
[48,49]. 
  
2.9. Toxicity and angiogenesis parameters 
Toxicity was evaluated by determination of the lethal concentration (LC50), which was 
the treatment concentration resulting in 50% mortality of the embryos over a period of 114 
hpf, and the effective concentration (EC50) that is the treatment concentration affecting 
50% embryos (lethal and teratogenic outcomes). In order to characterize teratogenic 
potential of the tested substances, the teratogenicity index (TI) was determined. TI was 
calculated as the ratio of LC50 and EC50. Anti-angiogenic activity was evaluated by 
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determination of anti-angiogenic concentration (IC50), which was the treatment 
concentration resulting in anti-angiogenic phenotype at 50% of embryos. To address anti-
angiogenic potential, the therapeutic window (TW), as the ratio of LC50 and IC50 was 
determined. Determination of LC50, EC50 and IC50 values was performed by the program 
ToxRatPro (ToxRat
®
, Software for the Statistical Analysis of Biotests, ToxRat Solution 
GmbH, Alsdorf, Germany, Version 2.10.05) using probit analysis with linear maximum 
likelihood regression.  
 
2.10. Molecular docking study 
The protein structures of matrix metalloprotease-2 (MMP-2; pdb code 1HOV, model 1), 
matrix metalloprotease-9 (MMP-9; pdb code 1GKC), human thioredoxin reductase 
(TrxR1; pdb code 2ZZ0) and vascular endothelial growth factor receptor (VEGFR-2; pdb 
code 3VHE) were extracted from Protein Data Bank, and used for docking study as targets 
for the tested compounds. The preparation of enzyme structure included the adding 
hydrogen atoms, removing water molecules and other ligands and ions from crystal 
structure (in MMPs both zinc ions were retained). In order to find binding sites and clarify 
the nature of interactions between tested compounds and targeted protein, molecular 
docking computations have been carried out using AutoDock 4.2 software program [50]. 
The structures of the tested compounds were optimized at the M06-2X/cc-
pVTZ+LanL2TZ(f) level of theory, while the atomic charges were calculated at same 
level, according to the Merz–Kollman scheme via the restrained electrostatic potential 
(RESP) model [51]. For zinc ions from proteins formal charge of +2 was used. All 
hydrogen atoms were added to the proteins. Optimized structures of the tested compounds 
and structures of the proteins were used to generate grid and docking parameter files in 
AutoDockTools program [50].
 
The rotatable bonds of tested compounds were allowed to 
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rotate freely, while the structure of protein was considered rigid. A grid box, containing the 
whole protein, was used to accommodate the tested compounds to move freely during 
docking study. AutoDock virtual screening used 10 runs for each docking experiment with 
Lamarckian genetic algorithm as the search method. The results of docking studies were 
analyzed and visualized using Discovery Studio, BIOVIA Software product [52].  
 
3. Results and Discussion 
3.1. Synthesis and structural characterization of 1 and 2 
Two aromatic N-heterocycles, 1,7-phenanthroline (1,7-phen) and 4,7-phenanthroline 
(4,7-phen), were used as ligands for gold(III) complexes (Fig. 1A). The two ligands have 
different steric and electronic properties and are likely to form complexes of different 
nuclearity. Steric considerations suggest that only monodentate κN7 coordination is to be 
expected for 1,7-phen, while nonlinear μ-N4,N7 bridging should be possible for 4,7-phen 
[53]. All reactions were performed by mixing the reactants in different molar ratios 
(n([AuCl4]
-
) : n(x,7-phen) = 1 : 1 and 2 : 1, respectively) at room temperature in ethanol. 
Although the investigated N-heterocycles possess benzene spacer between two pyridine 
rings, their reactions with [AuCl4]
-
 invariably lead to the formation of mononuclear 
gold(III) complexes, [AuCl3(1,7-phen-κN7)] (1) and [AuCl3(4,7-phen-κN4)] (2), having 
one monodentatedly coordinated N-heterocyclic ligand. The stoichiometries of 1 and 2 
were confirmed by elemental microanalysis, and the structures were elucidated by NMR 
(
1
H and 
13
C), IR and UV-vis spectroscopic and single-crystal X-ray diffraction analyses. 
DFT calculations were conducted to provide better insight into the coordination mode of 
1,7- and 4,7-phen toward the AuCl3 fragment. 
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3.1.1. Description of the single crystal structures 
As depicted in Fig. 1B, the investigated complexes contain Au(III) ion coordinated in a 
square-planar fashion by three chloride anions and nitrogen from Cs symmetrical 1,7-
phenanthroline (N7) and C2v symmetrical 4,7-phenanthroline (N4). Although similar in a 
formal sense, the monodentate coordination of 1,7- and 4,7-phen ligands to the AuCl3 core 
leads to notably different molecular and crystal structures, e.g. mutual orientation of AuCl3 
and phenanthroline moieties is nearly perpendicular (83.15(4)°) in 1 and more inclined 
(74.52(9)°) in 2, and the Au-Cl bonds are more diverse in 1 and more equalized in 2 (Table 
S3).  
 
 
Fig. 1. (A) Schematic drawing of 1,7- and 4,7-phenanthroline ligands. The numeration of 
carbon atoms is in agreement with IUPAC recommendations for fused ring systems. (B) 
Molecular structures of [AuCl3(1,7-phen-κN7)] (1) and [AuCl3(4,7-phen-κN4)] (2) 
complexes. Thermal ellipsoids are drawn at 50% probability level. H-atoms are 
represented in an arbitrary scale. 
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Diversity of the Au-Cl bond lengths in 1 presumably steams from the exceptionally rich 
variety of intermolecular interactions including Au···Cl, Cl···Cl, columnar stacking, 
numerous C-H∙∙∙Cl, as well as C-H∙∙∙N hydrogen bonds. Geometrical parameters describing 
these interactions are listed in Table S4 and depicted in Fig. 2. Compared to the crystals of 
1, in the crystals of 2, both Au···Cl and Cl···Cl contacts are longer (Table S4), so these 
molecules are more loosely packed, which is reflected in the density values for the two 
crystals and in the values of packing parameters listed in Table S1.
 
The more easy 
approach to the uncomplexed nitrogen atom N7 in 2 compared to the uncomplexed 
nitrogen atom N1 in 1 is reflected in much more favorable intermolecular C-H···N 
hydrogen bond parameters listed in Table S4.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Diversity of intermolecular interactions in the crystal structure of 1. H-bonds: 
dashed lines; Au···Cl: open lines; Cl···Cl: dotted lines; face-to-face stacking: shaded areas. 
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3.1.2. Spectroscopic characterization 
The NMR (
1
H and 
13
C), IR and UV-vis spectroscopic data for gold(III) complexes 1 and 
2 are listed in the section 2.3 (vide infra) and are consistent with the structures determined 
by single-crystal X-ray analysis. The 
1
H NMR spectra of the gold(III) complexes 1 and 2 
were noticeably different from those of uncoordinated 1,7- and 4,7-phen ligands. 
Monodentate coordination to Au(III) ion caused a desymmetrization of the ligands, 
resulting in appearance of eight proton signals in the spectra of complexes (instead of five 
and four proton signals in the spectra of uncoordinated 1,7- and 4,7-phen, respectively). 
The position of 1,7-phen ligand coordination (bonding to which of the two different 
nitrogen atoms, N1 or N7) was deduced from the largest values of the observed 
coordination shifts (determined in respect to the free ligand) in the 
1
H spectrum of the 
corresponding gold(III) complex 1. Δ(1H)coord values confirmed that this ligand is 
coordinated to Au(III) via the nitrogen atom N7: Δ(1H)coord was the highest (c.a. 0.8 ppm) 
for H-8, while the coordination shift for its counterpart, H-2, was significantly lower (c.a. 
0.2 ppm). The auration of 1,7- and 4,7-phen resulted in an overall 
1
H deshielding, what can 
be ascribed to a delocalization of the charge deficiency (cation formation (N
+
) by electron-
withdrawing AuCl3 group coordination) throughout the rings of the ligands [54,55]. 
Although on the whole, Au(III) complexation of the ligands produced an overall 
deshielding of ring carbons in complexes 1 and 2, the signals of several carbon atoms were 
shifted upfield. 
The IR spectra of the complexes 1 and 2 recorded in the range of 4000 – 450 cm-1 show 
the peaks that are atrributed to the coordinated phenanthroline ligands. In the Far-IR 
region, the most obvious feature is the very strong band at 363 and 359 cm
-1
 for 1 and 2, 
respectively, which can be assigned to the antisymmetric stretching vibration of Au–Cl 
bond, which is in the trans position in respect to the coordinated nitrogen atom. This is in 
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accord with the previous IR study of a series of gold(III) complexes of the general formula 
[AuCl3L], L stands for pyridine, 2-, 3- and 4-methylpyridine, 2,6-, 3,5- and 2,4-lutidine 
and 4-cyanopyridine, where it was assumed that the strong band in the range of 366 – 356 
cm
-1
 was due to the antisymmetric stretching vibration of the trans Au–Cl bond [56]. 
Moreover, shoulder at 340 and 342 cm
-1
 in the Far-IR spectra of 1 and 2, respectively, can 
be tentatively assigned to the symmetric stretching vibration of this bond, as it was found 
previously for the abovementioned [AuCl3L] complexes [56], in which spectra, very week 
and difficult to identify band due to this vibration was observed in the range of 345 – 333 
cm
-1
. 
The shape of the UV-vis spectra and values of λmax are almost identical for both of 
complexes (λmax = 322.0 and 321.0 nm for 1 and 2, respectively) confirming the same 
(monodentate) coordination mode of the phenanthroline ligands in 1 and 2. The absorbance 
peaks for 1 and 2 show significant red shifts compared to those for the uncoordinated N-
heterocycles (λmax = 267.0 and 270.0 nm for 1,7- and 4,7-phen, respectively), indicating 
that the absorption observed for the complexes can be attributed to LMCT (ligand-to-metal 
charge transfer) transitions [57].  
 
3.2. Theoretical studies 
The structures of the mononuclear gold(III) complexes 1 and 2, were optimized in the 
ethanol at the M06-2X(CPCM)/cc-pVTZ+LanL2TZ(f) level of theory. The optimized 
geometries of 1 and 2 are shown in Fig. S1, and the values of the calculated bond lengths 
and bond angles are given in Table S3. It can be seen that the calculated bond lengths and 
angles are in very good agreement with the corresponding X-ray structural data. This 
supports our recently obtained results showing that the M06-2X method provides an 
appropriate prediction of the crystal structure parameters of the gold(III) complexes with 
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aromatic N-heterocycles [55,57]. In addition, the M06-2X functional has been successfully 
applied to study the electron-donating properties of aromatic N-heterocycles [58].  
Considering the fact that 1,7-phen ligand contains two potential metal binding nitrogens 
with different environment, two possible mononuclear complexes that can be obtained in 
its reaction with [AuCl4]
-
, [AuCl3(1,7-phen-κN1)] and [AuCl3(1,7-phen-κN7)], were 
subjected to DFT calculations. The structures of these gold(III) complexes and their 
relative free energies calculated at the M06-2X(CPCM)/cc-pVTZ+LanL2TZ(f) level of 
theory are given in Fig. 3A. As can be seen from the relative free energies, the 
coordination of Au(III) ion to the nitrogen atom N7 is thermodynamically more favorable 
than the coordination to N1. This goes along the fact that the coordination of Au(III) to N1 
is followed by a loss of planarity in the aromatic 1,7-phen ligand. Besides that, the 
isodensity surfaces of the dual descriptor, that is very useful in prediction of the sites of 
electrophilic and nucleophilic attack, and its σ- and π-orbital contributions for the free 1,7-
phen ligand were examined (Fig. 3B-D). From the dual descriptor isodensity surface (Fig. 
3B), it is not clear how to differentiate nucleophilic character of the two nitrogen atoms in 
1,7-phen. Bearing in mind that 1,7-phen coordination to the Au(III) ion goes through σ 
lone pair of nitrogen, it is more reasonable to explore the σ-orbital dual descriptor 
isodensity surface. Fig. 3C clearly shows that N7 has more pronounced nucleophilic 
character than N1. This result implies that, beside steric, electronic effects also govern the 
coordination of Au(III) ion to N7 nitrogen. 
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Fig. 3. (A) The structures of two possible mononuclear gold(III) complexes, [AuCl3(1,7-
phen-κN7)] and [AuCl3(1,7-phen-κN1)], and their relative free energies calculated at the 
M06-2X(CPCM)/cc-pVTZ+LanL2TZ(f) level of theory. Dual descriptor isovalue surface 
(0.001 a.u.) for 1,7-phen: total (B), σ-orbital contribution (C) and π-orbital contribution 
(D). Nucleophilic and electrophilic regions are colored in red and blue, respectively.  
 
A detailed mechanistic study of the formation of mononuclear complexes 1 and 2 and 
their hypothetic dinuclear analogues, {[AuCl3]2(μ-1,7-phen)} and {[AuCl3]2(μ-4,7-phen)}, 
was performed (Figs. S2 and S3, and Table S5). It was shown that the formation of the 
mononuclear complexes is thermodynamically and kinetically favored over the formation 
of their dinuclear analogues, being in line with the experimental results (Fig. S4).  
 
3.3. Cytotoxicity and cell-migration 
The cytotoxic effect of complexes 1 and 2 in the healthy human fibroblasts and several 
cancer cell lines was between 1.1 and 2.1-fold higher in comparison to 1,7- and 4,7-phen 
(Table 1). This slightly improved cell-killing effects of the complexes in comparison to the 
respective ligands can be attributed to the presence of gold(III) center. However, the 
cytotoxic effect of both gold(III) complexes and phenanthrolines was much lower in 
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comparison to that of auranofin and comparable or higher in comparison to that of 
K[AuCl4]. None of the tested compounds exhibited significant selectivity between healthy 
MRC5 and cancer cell lines (Table 1). The cytotoxic potential of auranofin was confirmed, 
with IC50 values in accordance to the previous studies on the same or similar cell lines 
[59]. Phenanthrolines used in this study (Fig. 1A), although structurally similar to 1,10-
phenanthroline, showed between 5- and 50-fold reduced cytotoxic effect in comparison to 
1,10-phen against cisplatin-sensitive breast (MCF-7) and resistant ovarian (SKOV-3) 
cancer cell lines and A2780 ovarian cell line either sensitive or resistant to cisplatin 
[26,60]. For 1,10-phenanthroline, it has been hypothesized that the biological effects are 
due to its metal chelating properties [61,62]. To our best knowledge, the cytotoxic 
properties of 1,7- and 4,7-phen have not been reported previously, however it is apparent 
that different position of nitrogen atoms results in much lower cytotoxicity.  
The low in vitro cytotoxic effect of 1 and 2 is in line with our recent observation of the 
low cytotoxicity of gold(III) complexes with L-histidine-containing dipeptides [16]. 
Similarly, mononuclear gold(III) complexes containing various N-heterocycles 
(pyridazine, pyrimidine, pyrazine, quinoxaline and phenazine) were shown to have 
moderate to low cytotoxicity, but pronounced ability to intercalate double stranded DNA in 
vitro [63]. 
Overall, gold(III)-phenanthroline complexes 1 and 2 did not show pronounced cytotoxic 
nor anticancer potential, however their low cytotoxicity towards normal cell line made 
them suitable candidates for further examination towards the other biological activities. 
Prompted by the our recent study showing good anti-angiogenic potential of gold(III) 
complexes with L-histidine-containing dipeptides [16], we have decided to evaluate the 
anti-angiogenic potential of the gold(III) complexes 1 and 2. Considering that the cell 
migration is necessary for endothelial angiogenesis, as well as for cancer cell invasion and 
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metastasis, we have firstly performed classical scratch wound healing assay in human 
immortalized endothelial-like cell line EA.hy926 to determine the antimigratory effects of 
gold(III) complexes 1 and 2. Cells were treated with concentrations corresponding to 
double IC50 values of compounds (Table 1), and the migration of the cells into the wound 
area was monitored throughout a 6 h time window (Fig. 4). Under the tested conditions, the 
best antimigratory effects were observed upon treatment with complex 1 and 1,7-phen. In 
comparison to the migration rate of EA.hy926 cells without drug treatment, the wound 
closure effects for complex 1 and 1,7-phen were reduced to 42 and 47%, respectively. 
Complex 2 showed antimigratory effect comparable to that of auranofin. The EA.hy926 
cells incubated with 4,7-phen and K[AuCl4] migrated to approximately same extent as 
control cells within the same time window. Interestingly, quite different activity of two 
phenanthrolines was observed in this test, suggesting some specific inhibition caused by 
the difference in the position of nitrogen atoms (Fig. 1A). Indeed, the cells treated with 
1,7-phen showed different more rounded morphology from those upon 4,7-phen treatment 
(Fig. 4B), and the change of the cell shape was reported to influence the cell motility [64]. 
Auranofin expectedly showed inhibitory effect against wound-healing, in accordance with 
the previously reported study of its anti-angiogenic effect on human umbilical vein 
endothelial cells (HUVEC) [49]. The presented results indicate that both gold(III)-
phenanthroline complexes could influence the migration capability of endothelial cells. 
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Table 1 
Cytotoxic activity expressed as IC50 value (µM) for gold(III) complexes 1 and 2 in 
comparison to that for 1,7- and 4,7-phenanthroline, K[AuCl4] and clinically used drug 
auranofin, upon treatment for 48 h.  
a
IC50 is defined as the concentration inhibiting 50% of cell growth after the treatment with the test 
compounds. Results are from two independent experiments, each performed in quadruplicate, represented as 
mean ± SD. 
                                   Cell line 
Compound 
IC50 (µM)
a
 
MRC5 HeLa A549 EA.hy926 
[AuCl3(1,7-phen-κN7)] (1)
 80±4 62.5±2 70±3 100±5 
1,7-phen 135±14 70±4 150±10 120±7 
[AuCl3(4,7-phen-κN4)] (2) 120±5 115±8 85±2 130±6 
4,7-phen 170±9 125±5 155±6 140±8 
K[AuCl4] 150±12 170±4 160±8 165±5 
Auranofin 0.5±0.02 0.5±0.04 0.5±0.01 2.5±0.1 
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Fig. 4. Wound healing migration of EA.hy926 cells. Effects of gold(III) complexes 1 and 
2, phenanthroline ligands and K[AuCl4], applied in concentration of 200 µM, on the 
migration of EA.hy926 cells after treatment for 6 h (B) in comparison to solvent (DMF) 
control at time 0 h (A). Auranofin (5 µM) was used as reference anti-angiogenic 
compound. For each treatment condition, eight measurements were taken randomly in each 
well. Data are presented as mean ± SD of two independent experiments with * P < 0.05; ** 
P < 0.01; *** P < 0.001 according to one-way ANOVA followed by the Bonferonni 
comparison test (C). 
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3.4. Embryotoxicity and anti-angiogenesis potential 
In vivo toxicity assessment performed in this study on zebrafish embryos revealed that 
gold(III) complexes 1 and 2 were less toxic (both in terms of lethality and teratogenicity) 
than the respective phenanthroline ligands, and markedly less toxic than anti-angiogenic 
compounds auranofin and sunitinib (Fig. 5), ranking them according to toxicity, as follows: 
sunitinib > auranofin > 4,7-phen > 1,7-phen > K[AuC14] > 2 > 1. According to the 
determined LC50 values, gold(III) complexes 1 and 2 were 35- and 13-fold less toxic in 
comparison to auranofin, 118- and 45-fold less toxic than sunitinib, and 1.3- and 3-fold 
less toxic in comparison to the respective ligands. Notably, gold(III)-phenanthroline 
complexes showed neither developmental nor cardiovascular toxicity (pericardial edema 
and disturbed heartbeat rate) in zebrafish embryos in tested concentrations range of 2.5 – 
100 µM, where the embryos survival was affected only at doses ≥ 80 µM of 1 and ≥ 40 µM 
of 2 (Fig. 5). Contrary to the complexes, phenanthroline ligands caused teratogenic defects 
in embryos at the concentrations ≥ 40 µM, such as the multiple edemas (pericardial sac, 
egg yolk sac and body) and skeletal deformities (reduced growth, malformed head and 
eyes, lordosis), similarly to defects following auranofin and sunitinib treatments at doses ≥ 
1.25 µM. Results of the embryotoxicity of auranofin (Fig. 5) and sunitinib (data not 
shown) are in accordance with the previous studies on zebrafish embryo model [16,48]. 
These two clinically used drugs were found to cause the progressive cardiotoxicity 
(pericardial edema and decreased heartbeat rate) and skeletal deformities (reduced growth, 
malformed head and eyes, lordosis) already at concentration of 1.25 µM. K[AuC14] 
complex had no effect on zebrafish development and showed higher embryotoxicity in 
comparison to gold(III) complexes 1 and 2, but lower than that of phenanthroline ligands 
(Fig. 5). 
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Fig. 5. Toxicity assay on zebrafish embryos exposed to gold(III) complexes 1 and 2, 
ligands 1,7- and 4,7-phen, K[AuCl4] and auranofin expressed as LC50 values (μM). 
Morphology of zebrafish embryos at 114 hpf after treatment with 20 μM of 1, 2, ligands 
and K[AuCl4] (normal), and 1.25 μM of auranofin (teratogenic) are shown. Embryos upon 
auranofin treatment were retarded in the growth, had small or malformed head (bracket) 
and eyes (asterisk), large pericardial edema (arrow), non-resorbed egg yolk (NRY), signs 
of the tail lordosis (dashed arrow) and the necrotic tissue in the tail region (arrowhead). 
 
To the best of our knowledge, the in vivo toxicity of 1,7- and 4,7-phen has not been 
addressed previously in the zebrafish embryos model. Recently, Ellis and Crawford [20] 
examined the embryotoxicity of 1,10-phen and reported the same teratogenic defects in 
embryos upon 5 µM as we observed upon eight times higher concentration of 1,7- and 4,7-
phen. This suggests that 1,7- and 4,7-phen are less toxic than 1,10-phen, what has also 
been observed in cell-killing assays (Table 1), and may serve as suitable ligands for the 
metal complexes when activities other than antitumor are important. 
From the comparison of embryotoxicity profiles of gold(III)-phenanthroline complexes 
with gold(III) complexes with L-histidine-containing dipeptides and other aromatic 
nitrogen-containing heterocycles, previously assessed in zebrafish embryo model [16,63], 
it can be concluded that the nature of ligands decisively determines the toxicity response in 
embryos (survival, cardiotoxicity and teratogenicity). According to LC50 values, the 1,7-
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phenanthroline-containing complex 1 has stood out as the least toxic complex among all 
gold(III) complexes tested so far in zebrafish embryos model, with LC50 value of 128 µM. 
Interestingly, it has been observed that gold(III) complexes 1 and 2, but not the 
corresponding ligands, interfered with embryos hatching, like auranofin, but with different 
outcome (Fig. 5). While auranofin-treated embryos have already been prevented for 
hatching at 2.5 μM and died up to 114 hpf (hours post fertilization), the unhatched embryos 
occurring at 40 – 100 µM concentrations range of 1 and 2 survived up to 114 hpf. The 
hatching of zebrafish embryos is the process mainly driven by Zn-metalloproteases, which 
activity may be affected by diverse metal ions due to their binding to the enzyme’s active 
site or by sequestering of Zn(II) ions by chelating compounds [65]. Hatching interference 
has already been reported upon exposure of embryos to gold(III) complexes with aromatic 
nitrogen-containing heterocycles and L-histidine-containing dipeptides [16,63], but the 
mechanism still needs to be elucidated. 
It is important to emphasize that embryos following the treatment with gold(III)-
phenanthroline complexes 1 and 2, and the respective ligands showed reduced or absent 
caudal circulation, similarly to the pattern observed in embryos upon auranofin and 
sunitinib treatments. However, complex- and ligand-treated embryos did not have the body 
tissue necrosis, which has been developed upon the treatments with auranofin and sunitinib 
(Fig. 5). 
Prompted by studies that showed inhibition of angiogenesis caused by auranofin and 
selection of gold(I) and gold(III) complexes [16,49,66] in combination with the observed 
pattern of reduced caudal circulation during the embryotoxicity assessment, we have 
decided to examine in detail the potential of gold(III) complexes 1 and 2 and the 
corresponding phenanthroline ligands to affect angiogenesis in vivo in the zebrafish model. 
The suppression effect on angiogenesis by complexes 1 and 2 has been studied using 
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transgenic zebrafish [Tg(fli-1:EGFP)] embryos, in which the endothelial cells expressing 
EGFP can be directly observed by fluorescence microscope. The developmental 
angiogenesis in zebrafish embryos, leading to the formation of the intersegmental vessels 
(ISVs) at 48 hpf, and subintestinal vessels (SIVs) at 72 hpf, represents a valuable target for 
the screening of anti-angiogenic compounds. Anti-angiogenic phenotype was defined as 
the reduced number/length of subintestinal vessels (SIVs) or intersegmental vessels (ISVs) 
along the whole body (normally 5 – 9 arcades in the SIV basket-like structure and 28 – 30 
ISVs was developed), or as disrupted dorsal lateral vessels (DLAVs). Embryos were 
exposed to different doses of gold(III) complexes 1 and 2, the corresponding 
phenanthroline ligands and K[AuCl4], that were previously determined not to cause the 
effect on embryonal development (Figs. 6, S5 and S6, Table S2). The obtained results 
revealed that both gold(III) complexes and the respective ligands are efficient anti-
angiogenic compounds, while K[AuCl4] induced a negligible effect on the vessel 
development compared to the DMF (solvent vehicle)-treated group (P > 0.05, X
2
 test). 
Complexes 1 and 2 were significantly more active than the respective ligands, with the 
anti-angiogenic phenotype observed at concentration of 2.5 µM of complexes and ≥ 10 µM 
for 1,7- and 4,7-phen (Figs. 6B and S5, Table S6). Overall, 1 and 2 achieved the similar 
rate of ISVs and SIVs angiogenesis inhibition as the respective ligands applied in 4- to 8-
fold lower concentrations (Figs. 6 and S6, Table S6). 
When comparing anti-angiogenic effects of 1 and 2 to the clinically relevant auranofin 
and sunitinib, it was observed that gold(III)-phenanthroline complexes applied in dose of 
2.5 µM, achieved the same or higher inhibitory effects on ISVs angiogenesis in zebrafish 
embryos compared to 1.25 µM auranofin and sunitinib, which decreased the ISVs and 
SIVs length 33 and 59%, respectively, but caused serious pericardial edema and decreased 
the heart beating rate of treated embryos (Fig. S6, Table S6). When applied at the highest 
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tested dose of 20 µM, overall anti-angiogenic effect of 1 and 2 (the number of incomplete 
ISVs and the decrease in ISVs and SIVs length) was higher than that of 1.25 µM of 
sunitinib and auranofin (Fig. 6, Table S6), achieving 100 and 86% regression in SIVs 
basket length, and 77 and 65% regression in ISVs length, respectively (P < 0.001, 
ANOVA). Importantly, treatments with this dose of gold(III) complexes did not caused 
any developmental defects, neither affected embryos survival, while auranofin and 
sunitinib at 1.25 µM showed serious toxic effects in zebrafish embryos, particularly on 
cardial function (large pericardial edema and markedly reduced heartbeat; P < 0.001, 
ANOVA) what progressively decreased embryos’ survival up to 114 hpf (Figs. 6A and 
S7). Sunitinib is a clinically relevant metastatic drug, with pronounced cardiotoxicity being 
the major obstacle for its long-term application [67], which has also been demonstrated in 
this study. 
We firstly assessed the anti-angiogenic activity of the gold(III) complexes and the 
corresponding ligands by determining IC50 values (the concentration upon which 50% of 
embryos displayed anti-angiogenic phenotype) and EC50 values for SIVs and ISVs (the 
effective concentration resulting in 50% decrease of SIVs or ISVs length compared to the 
vehicle solvent-treated control group). According to all three determined parameters (Table 
2), tested compounds were ranked by their anti-angiogenic potential: sunitinib ≥ auranofin 
> 1 > 2 > 1,7-phen > 4,7-phen > K[AuCl4]. It can be seen that complex 1 showed the 
strongest in vivo anti-angiogenic activity in the zebrafish model among the presently 
investigated gold(III)-phenanthroline complexes and the corresponding ligands. Again, 
improved anti-angiogenic properties of complexes in comparison to the ligands can be 
ascribed to the presence of the gold(III) centre. 
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Table 2 
Toxicological parameters derived from the concentration-response curves for the 
assessment of toxicity and anti-angiogenic potential of gold(III) complexes 1 and 2, 1,7- 
and 4,7-phenanthroline, K[AuCl4] and clinically used drugs auranofin and sunitinib. 
  
LC50 EC50 TI IC50 TW 
EC50 
  ISVs SIVs 
1,7-phen 43.05 22.98 1.87 9.10 4.7 21.06 14.13 
[AuCl3(1,7-phen-κN7)] (1) 127.74 50.72 2.52 2.89 44.2 5.62 2.09 
4,7-phen 37.11 27.07 1.37 12.05 3.1 30.02 16.64 
[AuCl3(4,7-phen-κN4)] (2) 48.44 39.71 1.22 4.98 9.7 8.09 4.39 
K[AuCl4] 46.97 16.21 2.90 18.62 < 2.5 >  20 > 20 
Auranofin 3.67 0.40 8.31 0.56 6.6 1.92 1.08 
Sunitinib 1.08 0.72 1.50 0.50 2.16 1.76 1.06 
LC50 – the concentration inducing the lethal effect of 50% embryos.  
EC50 – the concentration affecting 50% embryos (survival and developmental defects). 
IC50 values - the concentration upon which 50% of embryos displayed anti-angiogenic phenotype. 
EC50 (SIVs and ISVs) - the effective concentration resulting in 50% decrease of SIVs basket or ISVs length 
compared to the DMF-treated control group. 
 
In order to address whether the tested compounds have more specific effect towards 
inhibition of blood vessels formation in comparison to overall embryotoxicity (mortality), 
EC50 (the effective concentration resulting in toxic response at 50% of embryos) and the 
therapeutic window (TW; the ratio between LC50 and IC50 values) have been determined 
(Table 2). The obtained results clearly showed that both complexes have higher anti-
angiogenic potential in comparison to both auranofin and sunitinib, particularly complex 1. 
Moreover, determined IC50 values were far below respective EC50 values for 1 and 2, but 
in case of auranofin and sunitinib very close or above the corresponding EC50, respectively 
(Fig. S8). These findings indicate wide therapeutic window for gold(III)-phenanthroline 
complexes 1 and 2, and an effective inhibition of angiogenesis at their subtoxic 
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concentrations, while an anti-angiogenic effect of auranofin and sunitinib would be 
achieved at the toxic concentrations range. 
 
Fig. 6. In vivo effect of gold(III)-phenanthroline complexes on angiogenesis in zebrafish 
embryos in comparison to that of 1,7- and 4,7-phenanthroline, K[AuCl4] and clinically 
used drugs auranofin and sunitinib. (A) Effects on the treatments on subintestinal vessels 
(SIVs), intersegmental vessels (ISVs) and dorsal longitudinal anastomotic vessels 
(DLAVs) development in [Tg(fli1:EGFP)] zebrafish embryos assessed at 48 hpf (for ISVs 
and DLAVs) and 72 hpf (for SIVs). Normally developed SIVs, ISVs and DLAVs are 
designated in 0.035% DMF-treated embryo. Reduced SIVs (arrowhead), disrupted DLAVs 
(asterisk), thinner or reduced ISVs (arrow), and pericardial edema (dashed arrow) are 
denoted. (B) Anti-angiogenic response of zebrafish embryos upon different treatments. The 
quantification of the inhibition of ISVs angiogenesis (C) and SIVs basket angiogenesis 
(D).  
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Although numerous gold(I) and gold(III) complexes were reported for in vitro anti-
proliferative potency, studies on their anti-angiogenic activity, solid tumor inhibition and 
toxicity in in vivo systems are rare [68-70]. The anti-angiogenic activity of auranofin, has 
only recently been discovered and described in vivo using [Tg(fli1:EGFP)] zebrafish 
embryos [49]. Prior to this, the inhibition of blood vessels development by gold(I) 
complexes with phosphine-naphthalimide and alkynyl(triphenylphosphine) has also been 
demonstrated in the zebrafish model [66,68]. These two gold(I) complexes influenced 
vessels development in 90% of the embryos only upon maximal non-lethal doses of 0.1 
and 1 µM, respectively [66,69]. As mentioned earlier, gold(III)-phenanthroline complexes 
1 and 2 were non-toxic even up to 20 µM, achieving comparable anti-angiogenic effect in 
zebrafish embryos to the mentioned gold(I) complexes upon the dose of 10 µM.  
Contrary to gold(I) complexes, the diversity of reported gold(III) complexes with anti-
angiogenic activity is far lower, involving 2-phenylpyridine gold(III) complexes with 
dithiocarbamate and gold(III) complexes with porphyrine, butilphenylpyridine and Schiff-
base ligands [12-15]. Besides that, porphyrine-containing-gold(III) complex was shown to 
decrease intra-tumoral vascularization in melanoma-bearing mice [11]. Recently, we 
reported gold(III) complexes with L-histidine-containing dipeptides with anti-angiogenic 
potency in zebrafish model, achieving a comparable effect to 1.25 µM auranofin, but upon 
30-fold higher concentrations [16]. Herein, we showed that gold(III)-phenanthroline 
complexes 1 and 2 have significantly higher anti-angiogenic activity and lower toxicity in 
comparison to the reported gold(III)-dipeptide complexes [16], confirming once again the 
crucial importance of the ligand nature for improvement of both efficacy and toxicity of 
anti-angiogenic compounds.  
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3.5. Molecular Docking Study 
It is well documented that angiogenesis blockade can be achieved by single- or multi-
targeting inhibition of major regulators of angiogenesis, such as the vascular endothelial 
growth factor receptors, the matrix metalloproteases and thioredoxin reductases. Among 
them, VEGFR-2 which drives endothelial cells survival, proliferation, and migration while 
increasing vascular permeability [71], MMP-2 and MMP-9 essential for the matrix 
remodeling around vessels and their sprouting, as well as cytosolic enzyme TrxR1, 
emerged as promising therapeutic strategies to combat angiogenesis-related diseases 
[71,72]. Although the exact molecular mechanisms responsible for anti-antiogenic activity 
of gold(III)-phenanthroline complexes and the corresponding ligands remain to be 
elucidated, recent study on the anti-angiogenic activity of 1,10-phenanthroline in zebrafish 
model system suggests that inhibition of matrix metalloproteases may be one of the 
possible mechanisms [20], although other mechanisms could not be ruled out. Therefore, 
we performed molecular docking study on VEGFR-2, MMP-2, MMP-9 and TrxR as in 
silico targets, with the aim to get insight into possible mechanisms of anti-angiogenic 
activity of gold(III)-phenanthroline complexes and the corresponding ligands. The results 
for the bonding mode of tested compounds and the binding energy for energetically most 
favorable binding modes are shown in Table 3 and Fig. 7. The best calculated pose for 
each of the studied compounds are presented in ESI, as well as two- and three-dimensional 
representation of their interactions with amino acids inside each target with identified 
hydrogen bonds and hydrophobic interactions (Figs. S9-16). 
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Table 3  
The binding energy (in kcal/mol) for energetically most favorable binding sites of tested 
compounds in the selected targets as assessed by molecular docking. 
Compound 
Target 
VEGFR-2 MMP-2 MMP-9 TrxR1 
[AuCl3(1,7-phen-κN7)] (1) -5.21 -3.99 -6.13 -4.77 
1,7-phen -3.94 -3.54 -4.29 -4.00 
[AuCl3(4,7-phen-κN4)] (2) -5.02 -3.67 -5.70 -4.71 
4,7-phen -4.01 -3.56 -4.27 -4.18 
Auranofin -1.79 -2.42 -1.76 -1.45 
Sunitinib -5.18 -3.62 -5.70 -6.34 
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Fig. 7. The bonding sites of tested compounds inside the vascular endothelial growth factor 
receptor (VEGFR-2; A), matrix metalloprotease-2 (MMP-2; B), matrix metalloprotease-9 
(MMP-9; C), and thioredoxin reductase (TrxR1; D). Tested compounds with the number of 
bonding sites higher than one are denoted with the number in brackets representing the 
order of the binding by affinity. 
 
Docking simulation with VEGFR-2 showed that all investigated compounds had the 
tendency to bind in ATP-binding site of VEGFR-2 (the active site), differing in the number 
of molecules that can be bound, as well as in the values of binding energy (Fig. 7A and 
Table 3). The complexes 1 and 2 had significantly higher affinity for the active site (-5.21 
and -5.02 kcal/mol, respectively) in comparison to 1,7- and 4,7-phen (-3.94 and -4.01 
kcal/mol, respectively). This may be explained by the fact that phenanthroline ligands 
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formed weak hydrogen bonds and hydrophobic interactions with amino acids in the active 
site of VEGFR-2 (Fig. S13), while the complexes have additionally established 
electrostatic interactions with peptide carbonyl group by the Au(III) ion, what increased 
their binding affinity to the receptor. Interestingly, the binding affinities of 1 and 2 were 
comparable to those of sunitinib (-5.18 kcal/mol) (Fig. S13), for which is known to 
suppress angiogenesis by inhibition of VEGFRs, including VEGFR-2 [73]. Among tested 
compounds, the lowest affinity for the receptor VEGFR-2 was shown by auranofin (-1.79 
kcal/mol), what may be attributed to its bulkiness and non-polar nature that sterically 
hindered its approach to the receptor’s active center. 
Result of docking study on MMP-2 and MMP-9 revealed the similar pattern of binding 
of each of tested compounds on both matrix metalloproteases, except of auranofin. While 
the complexes 1 and 2, and sunitinib were bound to the active site of both enzymes, ligands 
1,7- and 4,7-phen were bound to S1' pocket of these enzymes (Figs. 7C, S10, S11, S14 and 
S15). Such binding mode may be owing to a great sequence homology between MMP-2 
and MMP-9, particularly in the catalytic site (Fig. 7B, C) [74]. Docking computation 
showed that complexes 1 and 2 in comparison to 1,7- and 4,7-phen had markedly higher 
binding affinity for MMP-9 (-6.13 and -5.70 kcal/mol, respectively, vs. -4.29 and -4.27 
kcal/mol, respectively), and slightly higher for MMP-2 (-3.99 and -3.67 kcal/mol, 
respectively, vs. -3.54 and -3.56 kcal/mol, respectively). While ligands formed weak 
hydrogen bonds with non-polar amino acid residues from S1ʹ pocket of both MMPs, the 
coordination of phenanthrolines to Au(III) ion has led to increase of the compound surface, 
and therefore to increase of the number of amino acid residues with which each gold(III) 
complex 1 and 2 interacted. Additionally, the stacking and electrostatic interactions were 
established between Zn(II) ion of the catalytic centrum of enzymes and chlorido ligand in 
metal complexes (Fig. S14), what resulted in stronger binding of the complexes than 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 37 
ligands to these enzymes. It is noteworthy that complexes had comparable or higher 
affinity for binding for both matrix metalloproteases than sunitinib, as in the case of 
VEGFR-2 (Table 3). On the other side, the lowest affinity for both MMPs has been shown 
by auranofin, what may be explained by its non-polar nature and steric hindrance for its 
binding to enzymes (Figs. S14 and S15). 
Additionally, results of docking study showed that all tested compounds had greater 
binding affinity to MMP-9 than to MMP-2, except of auranofin which had higher affinity 
to MMP-2 (Table 3). It was previously shown that the conformational mobility of both 
active site and pockets of the matrix metalloproteases affected the inhibitory potency and 
selectivity of compounds [75]. Therefore, the conformational distortion of amino acid 
residues that occurs in the catalytic site of MMPs may explain the possible reason for 
higher affinity of tested compounds to MMP-9 than to MMP-2. However, the major 
difference between the catalytic domains of these matrix metalloproteases lies in the S1' 
pocket. While S1' pocket of MMP-2 is large hydrophobic channel and more deeper than 
S1' pocket of MMP-9, whereas the S1′ loop of MMP-2 is flexible to accommodate to more 
bulky ligands such as auranofin [74], S1′ pocket of MMP-9 is not sufficiently deep leaving 
auranofin bound outside the catalytic site of MMP-9 (Fig. 7C). Our results of docking 
computations for auranofin and sunitinib are in the agreement with the literature data 
which showed that auranofin attenuated MMP-2 activity, but leaving MMP-9 unaffected 
[76], while sunitinib decreased the activity of both MMP-2 and MMP-9 [77].  
We found that each of gold(III)-phenanthroline complexes, as well as the corresponding 
ligands, was capable to bind to TrxR1 (Fig. 7D and S12), what is in the line with the 
docking results from our recent study demonstrating the interaction of gold(III)-peptide 
complexes with TrxR1 [16], and an extensive literature data confirming that gold(I) and 
gold(III) complexes are very effective TrxR inhibitors [78,79]. Complexes 1 and 2 (-4.77 
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and -4.7 kcal/mol, respectively) were bound stronger to TrxR1 compared to 1,7- and 4,7-
phen (-4.00 and -4.18 kcal/mol, respectively), and markedly stronger than auranofin (-1.45 
kcal/mol), what is similarly to pattern observed for VEGFR-2, MMP-2 and MMP-9 (Table 
3). On, the other side, sunitinib (-6.34 kcal/mol) had the highest binding energy for TrxR1. 
Docking computation has also shown that complexes 1 and 2, and auranofin had the 
affinity to selenocysteine residue located on C-terminal (Cys498, Cys499), while 1,7-, 4,7-
phen and sunitinib had affinity to cysteine residues at the redox active site (Cys59, Cys64) 
at N-terminal domen (Figs. 7D and S16). The observed binding mode of 1, 2 and auranofin 
to TrxR1 is in a line with the previous study demonstrating the interaction of gold-based 
inhibitors with accessible selenocysteine residue at C-terminal domen [80]. Higher affinity 
of gold(III)-phenanthroline complexes to selenocysteine in comparison to auranofin may 
be explained as in previous protein/ligand systems (VEGFR-2, MMP-2 and MMP-9). As 
selenocysteine is essentially involved in the catalytic cycle of TrxR1, and presents an 
attractive binding site to inhibitors [81], it is assumed that gold(III)-phenanthroline 
complexes could be inhibitors of TrxR1 enzyme. On the other site, the binding of 1,7-, 4,7-
phen and sunitinib to the cysteine residues at the active site of TrxR1 is not probably 
accompanied by modifications of cysteine groups, what is otherwise necessary for the 
inhibition of TrxR1 activity, therefore these compounds should not be expected to act as 
inhibitors of TrxR1. As the support to our assumption is the finding of Zheng and 
coworkers, who demonstrated that sunitinib did not inhibit activity of TrxR1 in cancer cells 
[82]. 
 
4. Conclusions 
Gold(III) complexes with 1,7- and 4,7-phenanthroline ligands, [AuCl3(1,7-phen-κN7)] 
(1) and [AuCl3(4,7-phen-κN4)] (2), were synthesized, spectroscopically and 
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crystallographically characterized and biologically evaluated for in vitro cytotoxic and in 
vivo embryotoxic and anti-angiogenic potential. The mode of coordination of these ligands 
towards the Au(III) ion was found to be governed by both steric and electronic factors. 
Gold(III) complexes along with the corresponding phenanthroline ligands show no 
significant anticancer activity and selectivity in terms of cancer vs. normal cell lines; 
nevertheless, they exert low cytotoxicity against normal cell line. Besides that, in vivo 
assessment performed on zebrafish embryos revealed that both complexes 1 and 2 were 
significantly less toxic than auranofin and sunitinib with the known anti-angiogenic 
potential, showing neither developmental nor cardiovascular toxicity. Moreover, the 
overall anti-angiogenic potential of gold(III)-phenanthroline complexes was markedly 
higher than that of auranofin and sunitinib drugs, making them good anti-angiogenic drug 
candidates. Molecular docking computations indicated that complexes 1 and 2 could 
suppress the angiogenesis by affecting the multiple targets involved in this process. The 
obtained results are encouraging in the light of the synthesis of the novel anti-angiogenic 
compounds, since the development of anti-angiogenic drugs targeting multiple sites 
presents the major challenge in the current anti-angiogenic therapy. 
 
Appendix A. Supplementary data 
Supplementary Material associated with this article includes Figs. S1-S16 and Tables S1-
S6. Crystallographic data for 1 and 2 have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC 1539103-1539104). Copies may be obtained free of 
charge on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK 
(e-mail: deposit@chemcrys.cam.ac.uk). 
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Table and Figure Captions 
Table 1 
Cytotoxic activity expressed as IC50 value (µM) for gold(III) complexes 1 and 2 in 
comparison to that for 1,7- and 4,7-phenanthroline, K[AuCl4] and clinically used drug 
auranofin, upon treatment for 48 h.  
Table 2 
Toxicological parameters derived from the concentration-response curves for the 
assessment of toxicity and anti-angiogenic potential of gold(III) complexes 1 and 2, 1,7- 
and 4,7-phenanthroline, K[AuCl4] and clinically used drugs auranofin and sunitinib. 
Table 3  
The binding energy (in kcal/mol) for energetically most favorable binding sites of tested 
compounds in the selected targets as assessed by molecular docking. 
 
Fig. 1. (A) Schematic drawing of 1,7- and 4,7-phenanthroline ligands. The numeration of 
carbon atoms is in agreement with IUPAC recommendations for fused ring systems. (B) 
Molecular structures of [AuCl3(1,7-phen-κN7)] (1) and [AuCl3(4,7-phen-κN4)] (2) 
complexes. Thermal ellipsoids are drawn at 50% probability level. H-atoms are 
represented in an arbitrary scale. 
Fig. 2. Diversity of intermolecular interactions in the crystal structure of 1. H-bonds: 
dashed lines; Au···Cl: open lines; Cl···Cl: dotted lines; face-to-face stacking: shaded areas. 
Fig. 3. (A) The structures of two possible mononuclear gold(III) complexes, [AuCl3(1,7-
phen-κN7)] and [AuCl3(1,7-phen-κN1)], and their relative free energies calculated at the 
M06-2X(CPCM)/cc-pVTZ+LanL2TZ(f) level of theory. Dual descriptor isovalue surface 
(0.001 a.u.) for 1,7-phen: total (B), σ-orbital contribution (C) and π-orbital contribution 
(D). Nucleophilic and electrophilic regions are colored in red and blue, respectively.  
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Fig. 4. Wound healing migration of EA.hy926 cells. Effects of gold(III) complexes 1 and 
2, phenanthroline ligands and K[AuCl4], applied in concentration of 200 µM, on the 
migration of EA.hy926 cells after treatment for 6 h (B) in comparison to solvent (DMF) 
control at time 0 h (A). Auranofin (5 µM) was used as reference anti-angiogenic 
compound. For each treatment condition, eight measurements were taken randomly in each 
well. Data are presented as mean ± SD of two independent experiments with * P < 0.05; ** 
P < 0.01; *** P < 0.001 according to one-way ANOVA followed by the Bonferonni 
comparison test (C). 
Fig. 5. Toxicity assay on zebrafish embryos exposed to gold(III) complexes 1 and 2, 
ligands 1,7- and 4,7-phen, K[AuCl4] and auranofin expressed as LC50 values (μM). 
Morphology of zebrafish embryos at 114 hpf after treatment with 20 μM of 1, 2, ligands 
and K[AuCl4] (normal), and 1.25 μM of auranofin (teratogenic) are shown. Embryos upon 
auranofin treatment were retarded in the growth, had small or malformed head (bracket) 
and eyes (asterisk), large pericardial edema (arrow), non-resorbed egg yolk (NRY), signs 
of the tail lordosis (dashed arrow) and the necrotic tissue in the tail region (arrowhead). 
Fig. 6. In vivo effect of gold(III)-phenanthroline complexes on angiogenesis in zebrafish 
embryos in comparison to that of 1,7- and 4,7-phenanthroline, K[AuCl4] and clinically 
used drugs auranofin and sunitinib. (A) Effects on the treatments on subintestinal vessels 
(SIVs), intersegmental vessels (ISVs) and dorsal longitudinal anastomotic vessels 
(DLAVs) development in [Tg(fli1:EGFP)] zebrafish embryos assessed at 48 hpf (for ISVs 
and DLAVs) and 72 hpf (for SIVs). Normally developed SIVs, ISVs and DLAVs are 
designated in 0.035% DMF-treated embryo. Reduced SIVs (arrowhead), disrupted DLAVs 
(asterisk), thinner or reduced ISVs (arrow), and pericardial edema (dashed arrow) are 
denoted. (B) Anti-angiogenic response of zebrafish embryos upon different treatments. The 
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quantification of the inhibition of ISVs angiogenesis (C) and SIVs basket angiogenesis 
(D).  
Fig. 7. The bonding sites of tested compounds inside the vascular endothelial growth factor 
receptor (VEGFR-2; A), matrix metalloprotease-2 (MMP-2; B), matrix metalloprotease-9 
(MMP-9; C), and thioredoxin reductase (TrxR1; D). Tested compounds with the number of 
bonding sites higher than one are denoted with the number in brackets representing the 
order of the binding by affinity. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 54 
 
 
 
 
Graphical abstract 
 
 
The anti-angiogenic potential of mononuclear gold(III) complexes with 1,7- and 4,7-
phenanthroline ligands is markedly higher than that of the clinically relevant auranofin and 
sunitinib, making them good candidates for further development towards anti-angiogenic 
drugs. 
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Research Highlights 
 Novel gold(III)-phenanthroline complexes were synthesized and characterized. 
 Complexes and phenanthrolines have in vitro and in vivo anti-angiogenic activity. 
 Complexes inhibit angiogenesis more effectively than auranofin and sunitinib. 
 Complexes are less toxic both in vitro and in vivo than auranofin and sunitinib. 
 Complexes could target the multiple major regulators of angiogenesis. 
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